Tributary Capital Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 72,195 shares of the biopharmaceutical company’s stock, valued at approximately $2,619,000.
Several other large investors have also made changes to their positions in the stock. BlackRock Inc. boosted its stake in Pfizer by 1.5% during the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after purchasing an additional 6,785,335 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in Pfizer by 1.5% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 61,720,550 shares of the biopharmaceutical company’s stock valued at $2,190,462,000 after purchasing an additional 889,094 shares during the period. Dimensional Fund Advisors LP boosted its stake in Pfizer by 11.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock valued at $1,674,223,000 after purchasing an additional 4,998,981 shares during the period. Fisher Asset Management LLC boosted its stake in Pfizer by 4.4% during the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock valued at $1,431,069,000 after purchasing an additional 1,671,311 shares during the period. Finally, LSV Asset Management boosted its stake in Pfizer by 4.2% during the 1st quarter. LSV Asset Management now owns 35,801,094 shares of the biopharmaceutical company’s stock valued at $1,270,580,000 after purchasing an additional 1,440,402 shares during the period. 68.91% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE:PFE opened at $43.93 on Tuesday. The company has a market capitalization of $262.28 billion, a PE ratio of 15.35, a P/E/G ratio of 2.23 and a beta of 0.96. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $44.46. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The business had revenue of $13.47 billion for the quarter, compared to the consensus estimate of $13.30 billion. During the same period in the previous year, the firm earned $0.67 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.10%. Pfizer’s payout ratio is currently 51.32%.
In related news, insider Alexander R. Mackenzie sold 25,642 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $39.51, for a total value of $1,013,115.42. Following the sale, the insider now directly owns 127,954 shares in the company, valued at approximately $5,055,462.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the sale, the insider now owns 72,672 shares in the company, valued at $2,979,552. The disclosure for this sale can be found here. Insiders sold a total of 761,230 shares of company stock worth $29,054,690 over the last quarter. Insiders own 0.06% of the company’s stock.
A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, July 15th. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, June 13th. Credit Suisse Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Monday, June 11th. Jefferies Financial Group reissued a “neutral” rating and set a $39.00 target price on shares of Pfizer in a research note on Monday, July 9th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $42.00 price target on shares of Pfizer in a research note on Thursday, July 19th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. Pfizer currently has an average rating of “Hold” and a consensus price target of $41.89.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Article: Trading Strategy Methods for Individual Investors
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.